The current study utilizes a prospective multisite registry of patients treated in the contemporary era to assess the impact of low versus negative ER/PR expression on clinico-pathologic characteristics, treatment patterns, and survival outcomes in patients with HER2-negative breast cancers. This evidence concerns the gene PGR and breast cancer.